India, May 29 -- Shares of ORIC Pharmaceuticals, Inc. (ORIC) jumped over 30% on Thursday morning after the clinical-stage oncology company announced potentially best-in-class preliminary efficacy and safety data from the ongoing Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC).
ORIC is currently trading at $7.84, up $1.87 or 31.32%, on the Nasdaq. The stock opened at $7.29 after closing Wednesday at $5.97. The stock has traded between $3.89 and $14.67 in the past 52-week period.
"These ORIC-944 combination data demonstrate substantial clinical activity with both AR inhibitors, apalutamide and darolutamide, through early meas...